To advance eye care treatment, researchers at the University of Toronto have developed an approach to replace daily eye drops with a single injection under the eyelid, providing long-lasting relief for glaucoma patients.
The research team has developed a breakthrough drug delivery method that could transform glaucoma treatment. By modifying a common glaucoma drug into colloidal drug aggregates (CDAs) and delivering it via a hydrogel injection under the eyelid, they have extended its effectiveness from six hours to up to seven weeks. This innovative approach enhances efficacy, reduces patient burden and offers a less invasive alternative to vitreoretinal surgery.
With the potential to revolutionize eye care, the team is now working to refine the formulation for clinical use, bringing long-lasting, safer glaucoma treatment closer to reality.
For more information, visit the University of Toronto.
